Biogen pays $900M to settle wide-ranging physician kickback claims
Looking to clear the deck ahead of its long-awaited lecanemab data release, Biogen agreed to pay the US government and states a whopping $900 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.